In 2007, Bosma et. al provided a comprehensive review of emerging therapies for the acute
respiratory distress syndrome (ARDS), a condition which continues to carry a mortality rate …

Introduction: The acute respiratory distress syndrome (ARDS) is a common and catastrophic
condition, with a high mortality rate and economic burden on society. Despite 50 years of …

Introduction: Acute respiratory distress syndromes (ARDS) are devastating disorders of
overwhelming pulmonary inflammation and hypoxemia, resulting in high morbidity and …

The acute respiratory distress syndrome (ARDS) is a clinical syndrome with primarily
supportive management options. Despite extensive basic and clinical investigations …

Overall, there is no proven pharmacological therapy in ARDS, but some pharmacological
interventions were associated with beneficial effects in certain subgroups of patients …

Acute lung injury (ALI) and the acute respiratory distress syndrome (ARDS) are
characterized by rapid-onset respiratory failure following a variety of direct and indirect …

Introduction Acute respiratory distress syndrome (ARDS) is characterized by acute
inflammatory injury to the lungs, alterations in vascular permeability, loss of aerated tissue …

To date, the only therapeutic option that has convincingly been shown to decrease mortality
in acute respiratory distress syndrome (ARDS) has been to use a lung-protective strategy …

Acute lung injury/acute respiratory distress syndrome (ALI/ARDS) is a life-threatening form of
respiratory failure that affects a heterogeneous population of critically ill patients. Although …

Over 50 years have passed since the acute respiratory distress syndrome (ARDS) was first
described. 1 Despite the passage of more than one-half of a century, almost all of ARDS …